We use cookies to ensure that we give you the best experience on our website.
Luminus Biosciences

Preclinical Studies

Preclinical Study Results of ABC‑1103

Austin Biosciences has completed several key preclinical studies, including a maximum tolerated dose (MTD) study, a pharmacokinetics study, and biological activities in a breast tumor xenograft model, and in a pancreatic tumor xenograft model.

Results show ABC-1103 vs. Taxotere® has significantly greater anti-tumor activity with potentially reduced toxicity.